Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002812 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
A Phase 3 study of Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,078
- Enrollment target
- 20
- Study locations
NCT00002812 is a Phase 3 study of Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 2,078 participants, above the 478-participant average among 233 other Leukemia trials with a reported enrollment target (335% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT00002812, a Phase 3 study of Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,078 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Study Locations (20)
California
- Long Beach Memorial Medical Center - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Cancer Center and Cancer Research Institute - San Francisco
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
- Mount Sinai School of Medicine - New York
- Herbert Irving Comprehensive Cancer Center - New York
Minnesota
- University of Minnesota Cancer Center - Minneapolis
- Mayo Clinic Cancer Center - Rochester
Colorado
- Children's Hospital of Denver - Denver
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- University of Chicago Cancer Research Center - Chicago
Indiana
- Indiana University Cancer Center - Indianapolis
Iowa
- Holden Comprehensive Cancer Center at The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,078 participants |
| Start Date | 1996-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002812
The ClinicalTrials.gov registry entry for NCT00002812 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,078 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 478-participant average among 233 other Leukemia trials with a reported enrollment target (335% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002812 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00002812 about?
NCT00002812 is a clinical study titled "Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standa...
What is the current status of trial NCT00002812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,078 participants. The study started on 1996-09.
What conditions does trial NCT00002812 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00002812?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002812?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002812 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.